Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus gemcitabine and docetaxel versus gemcitabine and docetaxel in relapsed or refractory pediatric and young adult synovial sarcoma
NL-OMON55480Phase 2Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ramucirumab in synovial sarcoma (SS) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Planned start Jan 2020; status: withdrawn.
02
Drugs
ramucirumab
03
Conditions
synovial sarcoma (SS)
Beyond the preview
Go deeper on NL-OMON55480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55480.